- Home
- MUR vs DNTH Comparison
MUR vs DNTH Comparison
Compare MUR & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MUR | DNTH |
|---|---|---|
| Founded | 1950 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.6B | 4.5B |
| IPO Year | 1994 | 2018 |
Fundamental Metrics
Financial Performance| Metric | MUR | DNTH |
|---|---|---|
| Price | $38.85 | $103.13 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 14 | 13 |
| Target Price | $34.36 | ★ $121.00 |
| AVG Volume (30 Days) | ★ 1.5M | 1.1M |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.35% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.37 | N/A |
| Revenue | ★ $2,718,823,000.00 | $2,036,000.00 |
| Revenue This Year | $9.45 | N/A |
| Revenue Next Year | $3.94 | $29.48 |
| P/E Ratio | $106.49 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $21.86 | $18.08 |
| 52 Week High | $43.34 | $107.99 |
Technical Indicators
Market Signals| Indicator | MUR | DNTH |
|---|---|---|
| Relative Strength Index (RSI) | 64.37 | 58.23 |
| Support Level | $35.55 | $89.21 |
| Resistance Level | $40.83 | N/A |
| Average True Range (ATR) | 1.06 | 5.76 |
| MACD | 0.73 | 0.25 |
| Stochastic Oscillator | 85.54 | 72.73 |
Price Performance
Historical ComparisonAbout MUR Murphy Oil Corporation
Murphy Oil Corp is an oil and gas exploration and production company, with both onshore and offshore operations and properties. It operates in two geographic reportable segments the United States and Canada. It generates the majority of its revenue form the United States. The company also generates revenue from sales of oil and natural gas production activities.
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.